No Data
NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Trevi Therapeutics (TRVI) and DENTSPLY SIRONA (XRAY)
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Announces Target Price $18
NeoGenomics Hold Rating Maintained Amidst Ongoing Legal Challenges and MRD Assay Development Uncertainty
Needham Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $19